More downside before potential buy on CPRX
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to loss of $0.01 per share a year ago. wait for a decent retracement and buy.
Ý tưởng liên quan
Buy
BakiShirzadi
about CPRX